Valiant Labs Publishes Q3 FY26 Financial Results in Newspapers
Valiant Laboratories Limited published its Q3 FY26 financial results on February 13, 2026. Standalone results show Total Income of ₹15,386.12 lakh and Net Profit of ₹201.54 lakh. Consolidated results reported Total Income of ₹14,763.49 lakh and Net Loss of ₹(503.52) lakh for the quarter ended December 31, 2025.
Publication of financial results is a material event for investors and stakeholders, impacting investment decisions and company valuation.
The announcement is a routine publication of financial results and newspaper advertisements, with no overtly positive or negative performance indicators highlighted beyond the reported figures.
Valiant Laboratories Limited has officially published its audited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025. The results were announced on February 13, 2026, and appeared in The Financial Express (English) and Mumbai Lakshadeep (Marathi).
Key financial highlights for the quarter ended December 31, 2025, include a Total Income from Operations (Net) of ₹15,386.12 lakh for standalone and ₹14,763.49 lakh for consolidated. The Net Profit/(Loss) after Tax for the period stood at ₹201.54 lakh (standalone) and ₹(503.52) lakh (consolidated).
For the nine months ended December 31, 2025, the standalone Total Income from Operations (Net) was ₹5,360.83 lakh, with a Net Profit/(Loss) after Tax of ₹299.01 lakh. The consolidated figures for the same period show a Total Income from Operations (Net) of ₹5,431.25 lakh and a Net Profit/(Loss) after Tax of ₹(706.16) lakh.
The company also reported its Paid-up Equity Share Capital as ₹5,431.25 lakh and Reserves excluding Revaluation Reserves as ₹4,345.00 lakh (standalone) and ₹5,431.25 lakh (consolidated). Earnings per share (EPS) for the quarter were ₹0.37 (basic and diluted) on a standalone basis and ₹(0.93) (basic and diluted) on a consolidated basis. The company has also uploaded this information on its website, www.valiantlabs.in.
What to do with a filing like this
Valiant Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Valiant Laboratories Limited. Read the original for the full detail.